Interferon β-1a Avonex | 30 µg intramuscular weekly | Decrease disability and reduces frequency of clinical exacerbations by 32% in RRMS at 2 years Approved 1996 Pregnancy category C | Headache, influenza-like symptoms, depression Mild decrease in WCC and elevation in LFTs although rare |
Interferon β-1b Betaseron | 0.25 mg SC every other day | To reduce frequency of clinical exacerbations by 31% in RRMS at 2 years Approved 1993 Pregnancy category C | Headache, influenza-like symptoms, depression Injection site reactions Mild decrease in WCC and elevation in LFTs |
Interferon β-1b Extavia | 0.25 mg SC every other day | To reduce frequency of clinical exacerbations by 34% in RRMS Approved 2009 Pregnancy category C | Headache, influenza-like symptoms, depression Injection site reactions Mild decrease in WCC and elevation in LFTs |
Interferon β-1a Rebif | 22 µg or 44 µg SC 3xweekly | To reduce frequency of clinical exacerbations by 33% in RRMS at 2 years Approved 2002 Pregnancy category C | Headache, influenza-like symptoms, depression Injection site reactions Mild decrease in WCC and elevation in LFTs with one fatal case reported |
Pegylated interferon β-1a Plegridy | 125mcg SC once in 14 days | To reduce frequency of clinical exacerbations by 35.6% in RRMS Approved 2014 Pregnancy category C | Headache, influenza-like symptoms, depression Injection site reactions Mild decrease in WCC and elevation in LFTs |
Glatiramer acetate Copaxone | 20 mg SC once daily or 40 mg SC three times weekly | To reduce frequency of clinical exacerbations by 29% in RRMS at 2 years Approved 1997 3 times weekly 2014 Pregnancy category B | Injection site reactions are usually mild 10% with one time palpitations, chest pain, and SOB Injection site reactions including lipoatrophy |
Glatiramer acetate Glatopa | 20 mg SC once daily | To reduce frequency of clinical exacerbations by 30% in RRMS Approved 2015 Pregnancy category B | Approximately 10% of patients may experience transient symptoms after an injection such as palpitations, chest pain, diaphoresis, and shortness of breath |
Daclizumab Zinbryta | 150 mg SC once every 28 days | To reduce frequency of clinical exacerbations by 45% in RRMS As a second-line or third-line therapy Approved 2016 Pregnancy category None | Colds, URI, rash, eczema, skin hypersensitivity reactions, subcutaneous infections and infestations, depression, lymphadenopathy, colitis, and acute hepatitis Elevation of LFTs, some cases being severe |